Further evaluation in a larger population affected by HPV-negative/HER1-positive/PD-L1-positive tumors is necessary to fully assess the potential value of cetuximab alone or in combination with immunotherapy to inhibit the process of tumor cell invasion and regional and distant metastasis. This evidence concerns the gene EGFR and neoplasm.